Maturitas
Volume 59, Issue 3 , Pages 275-280 , 20 March 2008

Morphometric analysis of the urethra of castrated female rats treated with tamoxifen

  • Alesse Ribeiro dos Santos

      Affiliations

    • Department of Gynecology, Federal University of Piauí, Teresina, Piauí, Brazil
    • ,
  • Pedro Vitor Lopes-Costa

      Affiliations

    • Department of Gynecology, Federal University of Piauí, Teresina, Piauí, Brazil
    • ,
  • Júlio César Dias de Castro

      Affiliations

    • Department of Gynecology, Federal University of Piauí, Teresina, Piauí, Brazil
    • ,
  • Igor Cardoso Campos

      Affiliations

    • Department of Gynecology, Federal University of Piauí, Teresina, Piauí, Brazil
    • ,
  • Rafael Soares Borges

      Affiliations

    • Department of Gynecology, Federal University of Piauí, Teresina, Piauí, Brazil
    • ,
  • Cleicilene Gomes Pires

      Affiliations

    • Department of Gynecology, Federal University of Piauí, Teresina, Piauí, Brazil
    • ,
  • Karina Oliveira Drumond

      Affiliations

    • School of Veterinary Medicine, Federal University of Piauí, Teresina, Piauí, Brazil
    • ,
  • Airlane Pereira Alencar

      Affiliations

    • Department of Statistics, University of São Paulo, São Paulo, Brazil
    • ,
  • Benedito Borges da Silva

      Affiliations

    • Department of Gynecology, Federal University of Piauí, Teresina, Piauí, Brazil
    • Corresponding Author InformationCorresponding author at: Avenida Elias João Tajra, 1260, Apt. 600, Bairro Jockey Club, 64049-300, Teresina, Piauí, Brazil. Tel.: +55 86 3232 5063; fax: +55 86 3215 0470.

Received 3 January 2008 ,Revised 17 February 2008 ,Accepted 20 February 2008.

References 

  1. Fernandes CE, Morita MH, Ferreira JA, da Silva EP, Wehba S. Approach to urinary tract disorders in postmenopausal women. Rev Paul Med. 1990;108:230–235
  2. Ganz PA, Greendale GA, Petersen L, Zibecchi L, Kahn B, Belin TR. Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial. J Natl Cancer Inst. 2000;92:1054–1064
  3. Petros PE, Ulmsten UI. An integral theory and its method for the diagnosis and management of female urinary incontinence. Scand J Urol Nephrol Suppl. 1993;153:1–93
  4. Kim RJ, Kerns JM, Liu S, et al. Striated muscle and nerve fascicle distribution in the female rat urethral sphincter. Anat Rec (Hoboken). 2007;290:145–154
  5. Iosif CS, Batra S, Ek A, Astedt B. Estrogen receptor in the human female lower urinary tract. Am J Obstet Gynecol. 1981;141:817–820
  6. Rocha MA, Sartori MG, Girão MJ, De Jesus Simões M, Baracat EC, Rodrigues de Lima G. Histomorphometric study of the inferior urinary tract of adult female rats during the interval between castration and hormonal replacement. Clin Exp Obstet Gynecol. 2003;30:111–116
  7. Tanagho EA. Embryology of the urinary tract. In:  Tanagho EA,  Mcaninch JW editor. Smith's General Urology. 16th edn. Rio de Janeiro: Guanabara Koogan; 1990;p. 13–22
  8. Blakeman PJ, Hilton P, Bulmer JN. Oestrogen and progesterone receptor expression in the female lower urinary tract, with reference to oestrogen status. BJU Int. 2000;86:32–38
  9. Makela S, Strauss L, Kuiper G, et al. Differential expression of estrogen receptors α and β in adult rat accessory sex glands and lower urinary tract. Mol Cell Endocrinol. 2000;170:219–229
  10. Fisher B, Constantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371–1388
  11. Jordan VC. An overview of considerations for testing of tamoxifen as a preventive for breast cancer. Ann N Y Acad Sci. 1995;768:141–147
  12. Hall JM, McDonnell DP. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology. 1999;140:5566–5578
  13. da Silva BB, da Silva Júnior RG, Borges US, et al. Quantification of angiogenesis induced in rabbit cornea by breast carcinoma of women treated with tamoxifen. J Surg Oncol. 2005;90:77–80
  14. da Silva BB, de Carvalho Gonçalves Nunes Galvão ER, Dos Santos LG. Evaluation of CD34 antigen expression following tamoxifen as primary treatment for breast cancer. Int J Gynaecol Obstet. 2006;93:70–71
  15. de Sousa JA, Facina G, da Silva BB, Gebrim LH. Effects of low-dose tamoxifen on breast cancer biomarkers Ki-67, estrogen and progesterone receptors. Int Semin Surg Oncol. 2006;3:29
  16. Gennari L, Merlotti D, Valleggi F, Martini G, Nuti R. Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development. Drugs Aging. 2007;24:361–379
  17. Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol. 2004;94:256–266
  18. Iguchi T, Hirokawa M, Takasugi N. Occurrence of genital tract abnormalities and bladder hernia in female mice exposed neonatally to tamoxifen. Toxicology. 1986;42:1–11
  19. Day R, Ganz PA, Constantino JP, Cronin WM, Wickerham DL, Fisher B. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol. 1999;17:2659–2669
  20. Faria CA, Sartori MG, Baracat EC, de Lima GR, Girão MJ. Effects of tamoxifen on Doppler velocimetry parameters of periurethral vessels in postmenopausal women. Int Urogynecol J Pelvic Floor Dysfunct. 2005;16:56–59
  21. Masson P. Tumeurs humaines. Histologie diagnostics et techniques. 2nd edn. Paris: Libraire Maloine; 1956;p. 1061–1148
  22. Stokes ME, Davis CS, Koch GG. Categorical data analysis using the SAS system. Cary, NC: SAS Institute Inc.; 1995;
  23. Kutner MH, Nachtshein CJ, Neter J, Li W. Applied linear statistical models. 5th edn. Boston: McGraw-Hill Irwin; 2005;
  24. Albertazzi P, Sharma S. Urogenital effects of selective estrogen receptor modulators: a systematic review. Climateric. 2005;8:214–220
  25. Vardy MD, Lindsay R, Scotti RJ, et al. Short-term urogenital effects of raloxifene, tamoxifen, and estrogen. Am J Obstet Gynecol. 2003;189:81–88
  26. Goldstein SR, Nanavati N. Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study. Am J Obstet Gynecol. 2002;187:521–527
  27. Hendrix SL, McNeeley SG. Effect of selective receptor modulators on reproductive tissues other than endometrium. Ann N Y Acad Sci. 2001;949:243–250
  28. Cigler T, Goss PE. Breast cancer adjuvant endocrine therapy. Cancer J. 2007;13:148–155
  29. Land SR, Wickerham DL, Costantino JP, et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention—the NSABP study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295:2742–2751
  30. Bese NS, Umay C, Yildirim S, et al. The effects of tamoxifen on radiation-induced pulmonary fibrosis in Wistar albino rats: results of an experimental study. Breast. 2006;15:456–460
  31. Lien EA, Solheim E, Ueland PM. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res. 1991;51:4837–4844
  32. Iosif CS, al-Hijji J, Samsioe G. Effects of tamoxifen and estradiol on estrogen binding sites in the urogenital tract: an experimental study in the rabbit. Gynecol Endocrinol. 2002;16:379–383
  33. da Silva BB, Lopes IM, Gebrim LH. Effects of raloxifene on normal breast tissue from premenopausal women. Breast Cancer Res Treat. 2006;95:99–103

PII: S0378-5122(08)00072-8

doi: 10.1016/j.maturitas.2008.02.010

Maturitas
Volume 59, Issue 3 , Pages 275-280 , 20 March 2008

Article Tools

* Image Usage & Resolution